Preclinical data for SIL204 reported up to 99.7% cancer cell inhibition across multiple KRAS mutations, and recently completed two-species toxicology studies showed no systemic organ toxicity. A safety run-in is planned ahead of a Phase 2/3 program slated to begin in Q2 2026.
The core move: Silexion has initiated its first regulatory application in Israel to open a Phase 2/3 study of SIL204 in locally advanced pancreatic cancer, referencing positive Scientific Advice from Germany’s BfArM. Parallel submissions in Germany and the EU are planned for Q1 2026, with U.S. site activation expected after the Israel/Germany safety run-in. The trial will be conducted in collaboration with Sheba Medical Center in Israel, pending local approvals. SIL204 is an siRNA candidate targeting mutated KRAS with a dual-route administration strategy that combines intratumoral dosing for the primary lesion with systemic administration for metastatic risk.
Strategically, this is a staged, de-risked entry into human testing that leans on a fast-start geography and a marquee early site while aligning with EU regulators before engaging the U.S. The sequencing—run safety and feasibility at a high-volume, interventional-capable center, lock protocol and dosing logistics with BfArM input, then expand into the EU and U.S.—minimizes early IND friction and allows the company to pressure-test a complex delivery paradigm. The choice of LAPC is pragmatic: KRAS mutation prevalence reduces biomarker burden, while intratumoral access via EUS- or image-guided injection is operationally feasible and offers a path to measure local tumor control and potential conversion-to-resection—endpoints that can demonstrate differentiated value without immediately competing in metastatic settings dominated by combination chemotherapy.
For sites, the dual-route design is the headline operational challenge. Intratumoral pancreatic administration concentrates activity in interventional endoscopy or interventional radiology suites, adds procedure scheduling complexity, and raises monitoring requirements for pancreatitis, bleeding, and procedure-related adverse events. Systemic siRNA dosing will require RNA-handling SOPs, potentially enhanced cold-chain and pharmacy preparation, and staff training on infusion- or injection-related reactions and innate immune activation signals. Expect imaging-heavy assessments and detailed procedure documentation, increasing data management and source verification burdens. CROs will need to orchestrate cross-functional teams spanning GI/IR, oncology, pharmacy, and radiology, with careful country-by-country regulatory navigation under the EU CTR/CTIS timeline. For regulators, a seamless Phase 2/3 construct will put attention on safety gating criteria, stopping rules, and the statistical architecture enabling transition to confirmatory cohorts. For sponsors watching the space, the design tests whether combining localized RNA interference with systemic exposure can produce clinically meaningful control in a notoriously resistant disease without prohibitive operational friction.
What to watch next is protocol detail. Whether SIL204 is layered onto FOLFIRINOX- or chemoradiation-based standards will dictate enrollment velocity, safety interpretability, and comparative relevance. Clarity on the intratumoral delivery method, dosing interval synchronization between local and systemic routes, and conversion-to-resection versus PFS/OS hierarchy will signal the regulatory negotiation strategy. Manufacturing readiness for siRNA at scale, release testing, and device/accessory standardization will be gatekeepers for multi-region rollout. On the scientific side, the breadth of KRAS allele coverage, durability of local control, and early hints of systemic disease containment will determine whether the dual-route approach justifies its added complexity. The near-term risk is procedural: pancreas-directed injections can erode enthusiasm if complication rates creep above what interventional teams accept. If the safety run-in is clean and logistics are reproducible at Sheba and early EU sites, Silexion will have the operational credibility to expand—and the field will get a real-world test of localized RNAi as a complement to systemic therapy in pancreatic cancer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
